Effectiveness of potent antiretroviral therapies on the incidence of opportunistic infections before and after AIDS diagnosis.
OBJECTIVE
To determine the effectiveness of potent antiretroviral therapy in reducing opportunistic infections (OI) as both a presenting event and subsequent to an AIDS-defining event.


METHODS
A total of 543 seroconverters and 1470 men with AIDS were compared for the time to development of OI as the presenting AIDS event and as a subsequent event in the 1984-1989, 1990-1992, 1993-1995, and 1996-1998 periods, when the major treatments were no therapy, monotherapy, combination therapy, and potent antiretroviral therapy, respectively.


RESULTS
The seroconverters suffered 132 OI and the participants with AIDS had 717 OI. The relative hazard (RH) of OI as the presenting AIDS event declined by 81% in the calendar period when potent antiretroviral therapy was available compared with the monotherapy period. Declines were observed for Mycobacterium avium complex, cytomegalovirus disease, and esophageal candidiasis, but were statistically significant only for Pneumocystis carinii pneumonia. The RH of OI as a secondary infection dropped by 77% in the last calendar period compared with the monotherapy period. A significant decline was observed for all four OI. Prophylactic drug use did not increase in the era of potent antiretroviral therapy.


CONCLUSIONS
The hazard of OI in the era of potent antiretroviral therapy has declined dramatically compared with the era of monotherapy, despite the concurrent decrease in the use of prophylactic drugs. Physicians should consider whether it is necessary to include prophylactic drugs as part of the complex drug regimen for patients on potent antiretroviral therapy.
School of Public Health, University of California, Los Angeles, 90095-1772, USA. detels@ucla.edu
R
R
Detels
P
P
Tarwater
J P
JP
Phair
J
J
Margolick
S A
SA
Riddler
A
A
Muñoz
D017088:AIDS-Related Opportunistic Infections / Q000453:epidemiology* / Q000517:prevention & control; D000163:Acquired Immunodeficiency Syndrome / Q000188:drug therapy*; D000328:Adult; D001741:Black or African American; D023241:Antiretroviral Therapy, Highly Active; D044383:Black People; D002180:Candidiasis, Oral / Q000453:epidemiology; D015331:Cohort Studies; D018450:Disease Progression; D006679:HIV Seropositivity / Q000188:drug therapy*; D006801:Humans; D015994:Incidence; D008297:Male; D015270:Mycobacterium avium-intracellulare Infection / Q000453:epidemiology; D016720:Pneumocystis Infections / Q000453:epidemiology / Q000517:prevention & control; D015995:Prevalence; D012307:Risk Factors; D013997:Time Factors; D014481:United States / Q000453:epidemiology